Royalty Pharma (RPRX) Other Accumulated Expenses (2020 - 2026)

Royalty Pharma has disclosed Other Accumulated Expenses across 7 years of filings, most recently posting $16.3 million for Q2 2026.

• In Q2 2026, Other Accumulated Expenses rose 430.6% year-over-year to $16.3 million; the TTM figure through Jun 2026 stood at $16.3 million (up 430.6% YoY), while the FY2025 annual figure was $53.2 million, down 22.5% from the prior year.
• Other Accumulated Expenses came in at $16.3 million for Q2 2026 at Royalty Pharma, down from $17.5 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $97.5 million in Q2 2024 to a low of $3.1 million in Q2 2025.
• Average Other Accumulated Expenses over 5 years is $28.5 million, with a median of $16.9 million recorded in 2026.
• Year-over-year, Other Accumulated Expenses jumped 503.08% in 2024 and tumbled 96.85% in 2025.
• Over 5 years, Other Accumulated Expenses stood at $12.4 million in 2022, then dropped by 8.27% to $11.4 million in 2023, then jumped by 503.08% to $68.6 million in 2024, then fell by 22.5% to $53.2 million in 2025, then plunged by 69.31% to $16.3 million in 2026.
• Per Business Quant data, the three most recent Other Accumulated Expenses figures were $16.3 million in Q2 2026, $17.5 million in Q1 2026, and $53.2 million in Q4 2025.